These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7045018)

  • 1. Antidepressant effect of Ro 11-1163, a new MAO inhibitor.
    Stefanis CN; Alevizos BH; Papadimitriou GN
    Int Pharmacopsychiatry; 1982; 17(1):43-8. PubMed ID: 7045018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moclobemide (Aurorix) in primary major depression.
    Rihmer Z; Barsi J; Vad G; György S; Zalay B; Vég K; Gábor A
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Mar; 18(2):367-72. PubMed ID: 8208985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.
    Casacchia M; Carolei A; Barba C; Frontoni M; Rossi A; Meco G; Zylberman MR
    Pharmacopsychiatry; 1984 Jul; 17(4):122-5. PubMed ID: 6382361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind comparison of moclobemide and tranylcypromine in depression.
    Heinze G; Rossel L; Gabelic I; Galeano-Munoz J; Stabl M; Allen SR
    Pharmacopsychiatry; 1993 Nov; 26(6):240-5. PubMed ID: 8127928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group.
    J Affect Disord; 1993 Jun; 28(2):105-16. PubMed ID: 8354766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moclobemide and clomipramine in the treatment of depression. A randomized clinical trial.
    Larsen JK; Holm P; Mikkelsen PL
    Acta Psychiatr Scand; 1984 Sep; 70(3):254-60. PubMed ID: 6388247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical study of the selective MAO-A-inhibitor moclobemide (Ro 11-1163): a comparison of 2 different dosages with particular reference to platelet MAO-activity and urinary MHPG-excretion.
    Lensch K; Fuchs G; Böning J; Milech U
    Int Clin Psychopharmacol; 1987 Apr; 2(2):165-71. PubMed ID: 3298420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders.
    Williams R; Edwards RA; Newburn GM; Mullen R; Menkes DB; Segkar C
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):155-8. PubMed ID: 8468437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RIMA--a new concept in the treatment of depression with moclobemide.
    Amrein R; Hetzel W; Stabl M; Schmid-Burgk W
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):123-32. PubMed ID: 8468432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moclobemide--placebo-controlled trials.
    Silverstone T
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):133-6. PubMed ID: 8468433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.
    König F; Wolfersdorf M
    Pharmacopsychiatry; 1997 May; 30(3):93-6. PubMed ID: 9211570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind comparison of moclobemide, imipramine and placebo in depressive patients.
    Ucha Udabe R; Márquez CA; Traballi CA; Portes N
    Acta Psychiatr Scand Suppl; 1990; 360():54-6. PubMed ID: 2123367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.
    Botte L; Evrard JL; Gilles C; Stenier P; Wolfrum C
    Acta Psychiatr Belg; 1992; 92(6):355-69. PubMed ID: 1345409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.
    Laux G; Classen W; Sofic E; Becker T; Riederer P; Lesch KP; Struck M; Beckmann H
    J Neural Transm Suppl; 1990; 32():189-95. PubMed ID: 2089089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moclobemide versus placebo in the treatment of depression: a multicentre study in Belgium.
    Botte L; Gilles C; Evrard JL; Mesters P; Wolfrum C; Berger M; Hellstern K; Ward J
    Acta Psychiatr Scand Suppl; 1990; 360():42. PubMed ID: 2248066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moclobemide versus imipramine in depressed out-patients: a double-blind multi-centre study.
    Rimón R; Jääskeläinen J; Kaartinen P; Kalli A; Kilponen E; Koskinen T; Nikkilä H; Pirttiperä V; Seppälä J
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):141-7. PubMed ID: 8468435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric alterations in treatment with the MAO-A-inhibitor moclobemide.
    Classen W; Laux G
    J Neural Transm Suppl; 1990; 32():185-8. PubMed ID: 2089088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder.
    Laux G; Beckmann H; Classen W; Becker T
    J Neural Transm Suppl; 1989; 28():45-52. PubMed ID: 2677241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moclobemide (Ro 11-1163) versus tranylcypromine in the treatment of endogenous depression.
    Gabelic I; Kuhn B
    Acta Psychiatr Scand Suppl; 1990; 360():63. PubMed ID: 2248076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients.
    Markianos M; Alevizos B; Hatzimanolis J; Stefanis C
    Psychiatry Res; 1994 Jun; 52(3):259-64. PubMed ID: 7527564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.